The article "LINC01296 promotes the proliferation and invasion by regulating microRNA-760 expression and predicts poor prognosis of hepatocellular carcinoma", by Z.-C. Wang, S. Yang, M.-Q. Chen, S.-S. Wu, H.-H. Lv, W.-X. Jin, published in Eur Rev Med Pharmacol Sci 2019; 23 (22): 9848-9856-DOI: 10.26355/eurrev_201911_19548- PMID: 31799652 has been retracted by the author for the following reasons: After the publication of this article, the authors reviewed the process of the experiment and found there were mistakes in the methodology search. Not all the carcinoma specimens used in the experiment were from hepatocellular carcinoma. The prognosis and clinical features the rate of lymph node metastasis and the treatment and prognosis between these types of cancers are different. For example, intrahepatic cholangiocarcinoma tends to involve a high frequency of lymph node metastasis, and the prognosis is worse than hepatocellular carcinoma; hepatocellular carcinoma seldom involves lymph node metastasis but often involves intrahepatic metastasis; colorectal cancer liver metastasis is far more sensitive to chemotherapy and has a relatively long survival, and neuroendocrine carcinoma is sometimes sensitive to hormone therapy and generally has better survival than hepatocellular carcinoma. As a result, the clinical results and gene test results mentioned in this article were incorrect. After that the authors found that there was a mistake, they subsequently carried out supplementary experiments and found that they could not confirm that there was an increase in the expression of the LICO01296 gene in hepatocellular carcinoma, so they could not link some clinical results with the results of the basic research results mentioned in this article. Therefore, from the perspective of academic rigor, they requested to withdraw the article. The Publisher apologizes for any inconvenience this may cause. https://www.europeanreview.org/article/19548.